Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.

J R Thistlethwaite; Björn Nashan; M Hall; L Chodoff; T H Lin

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.

Standard

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. / Thistlethwaite, J R; Nashan, Björn; Hall, M; Chodoff, L; Lin, T H.

In: TRANSPLANTATION, Vol. 70, No. 5, 5, 2000, p. 784-790.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Thistlethwaite, JR, Nashan, B, Hall, M, Chodoff, L & Lin, TH 2000, 'Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.', TRANSPLANTATION, vol. 70, no. 5, 5, pp. 784-790. <http://www.ncbi.nlm.nih.gov/pubmed/11003358?dopt=Citation>

APA

Thistlethwaite, J. R., Nashan, B., Hall, M., Chodoff, L., & Lin, T. H. (2000). Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. TRANSPLANTATION, 70(5), 784-790. [5]. http://www.ncbi.nlm.nih.gov/pubmed/11003358?dopt=Citation

Vancouver

Thistlethwaite JR, Nashan B, Hall M, Chodoff L, Lin TH. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. TRANSPLANTATION. 2000;70(5):784-790. 5.

Bibtex

@article{d8ad985f773d44f1a74d2623409b0e5a,

title = "Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.",

abstract = "BACKGROUND: Renal allograft recipients with diabetes mellitus often demonstrate poorer clinical outcomes than nondiabetic patients. Basiliximab (Simulect), a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the incidence of acute rejection in renal allograft recipients in 2 multicenter, placebo-controlled, phase III trials. METHODS: An analysis of pooled results from the 2 trials was conducted to compare the efficacy and safety of basiliximab with placebo in renal transplant recipients with and without prior diabetes. Patients received either basiliximab (20 mg on day 0 and day 4 posttransplantation) or placebo in combination with cyclosporine for microemulsion (Neoral) and steroids. RESULTS: A total of 722 patients (150 diabetic, 572 nondiabetic) were eligible for intent-to-treat analysis. At 12 months, basiliximab as compared with placebo reduced the proportion of patients experiencing first acute rejection by 41% in diabetics (P",

author = "Thistlethwaite, {J R} and Bj{\"o}rn Nashan and M Hall and L Chodoff and Lin, {T H}",

year = "2000",

language = "Deutsch",

volume = "70",

pages = "784--790",

journal = "TRANSPLANTATION",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

RIS

TY - JOUR

T1 - Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.

AU - Thistlethwaite, J R

AU - Nashan, Björn

AU - Hall, M

AU - Chodoff, L

AU - Lin, T H

PY - 2000

Y1 - 2000

N2 - BACKGROUND: Renal allograft recipients with diabetes mellitus often demonstrate poorer clinical outcomes than nondiabetic patients. Basiliximab (Simulect), a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the incidence of acute rejection in renal allograft recipients in 2 multicenter, placebo-controlled, phase III trials. METHODS: An analysis of pooled results from the 2 trials was conducted to compare the efficacy and safety of basiliximab with placebo in renal transplant recipients with and without prior diabetes. Patients received either basiliximab (20 mg on day 0 and day 4 posttransplantation) or placebo in combination with cyclosporine for microemulsion (Neoral) and steroids. RESULTS: A total of 722 patients (150 diabetic, 572 nondiabetic) were eligible for intent-to-treat analysis. At 12 months, basiliximab as compared with placebo reduced the proportion of patients experiencing first acute rejection by 41% in diabetics (P

AB - BACKGROUND: Renal allograft recipients with diabetes mellitus often demonstrate poorer clinical outcomes than nondiabetic patients. Basiliximab (Simulect), a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the incidence of acute rejection in renal allograft recipients in 2 multicenter, placebo-controlled, phase III trials. METHODS: An analysis of pooled results from the 2 trials was conducted to compare the efficacy and safety of basiliximab with placebo in renal transplant recipients with and without prior diabetes. Patients received either basiliximab (20 mg on day 0 and day 4 posttransplantation) or placebo in combination with cyclosporine for microemulsion (Neoral) and steroids. RESULTS: A total of 722 patients (150 diabetic, 572 nondiabetic) were eligible for intent-to-treat analysis. At 12 months, basiliximab as compared with placebo reduced the proportion of patients experiencing first acute rejection by 41% in diabetics (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 70

SP - 784

EP - 790

JO - TRANSPLANTATION

JF - TRANSPLANTATION

SN - 0041-1337

IS - 5

M1 - 5

ER -